Government Shutdown Avoided With $1.2 Trillion Plan

Congress succeeded in narrowly averting a partial government shutdown by passing a $1.2 trillion spending package, but the contentious process laid bare the dysfunctional politics plaguing Washington D.C. This brinkmanship threatens to erode economic confidence and financial market stability, posing risks that small cap investors must monitor closely.

The House of Representatives advanced the 1,012-page omnibus bill by the slimmest of margins on Friday, with the 286-134 vote squeaking by the two-thirds majority required under an expedited procedure. A faction of 112 Republican lawmakers opposed the bipartisan compromise negotiated by House Speaker Mike Johnson, characterizing it as a bloated spending measure drafted secretly. The rancorous divide even prompted Rep. Marjorie Taylor Greene to file a long-shot bid to remove Johnson from his leadership role.

The legislative turmoil then shifted to the Senate, where certain conservative members like Rand Paul and Tommy Tuberville signaled they could employ dilatory tactics to temporarily force a shutdown before the bill’s ultimate anticipated passage this weekend. While a short-term partial shutdown would have limited fallout for government operations with retroactive funding, the perpetual governance crises fomented by such maneuvers are deeply concerning for the economic outlook.

“This inability to govern pragmatically and reach reasonable compromise shakes confidence in American economic leadership at a pivotal juncture,” said Brendan Walsh, a partner at investment advisor Woodridge Partners. “The brinkmanship and uncertainty could undermine the environment for sustained earnings growth that small-cap companies rely upon.”

Lack of fiscal discipline, long-term economic foresight, and stable policymaking tends to breed volatility that markets abhor. With the looming prospect of a debt ceiling standoff on the horizon, the headwinds for equity investors are magnified. Buoyant stock valuations appear increasingly discordant with the actual deteriorating governance backdrop, suggesting potential downside risks are being underappreciated.

Indeed, major credit rating agencies have already taken action reflecting these dynamics. Fitch downgraded its U.S. sovereign debt rating in August 2022, citing escalating budgetary dysfunction as a primary factor. Similarly, Moody’s revised its U.S. outlook to negative last November amid the fiscal policy disarray, signaling another downgrade could materialize.

“The perpetual political dramas surrounding basic government funding operations speak to deeper systemic issues that have now directly threatened America’s pristine credit rating,” said Liz Young, head of investment strategy at Renaissance Capital. “This turmoil should be highly concerning for small-cap investors sensitized to economic shifts.”

While equity markets exhibited nonchalance toward this latest shutdown scare, previous prolonged political standoffs over the debt ceiling and government funding have periodically roiled stocks. The S&P 500 fell over 10% in summer 2011 as partisan factions brawled over raising the debt limit before an eleventh-hour resolution, exemplifying how swiftly sentiment can sour during such imbroglios.

With the upcoming debt ceiling fight potentially catalyzing another such conflict before year-end, watchful small-cap investors must be vigilant for escalating dysfunction that could provoke turbulent volatility.

“At a certain threshold, this unproductive political rancor manifests tangible economic and market consequences that can no longer be easily dismissed,” Walsh cautioned. “Preparing defensive postures and hedging strategies may be prudent to navigate potential volatility spawned by these self-inflicted crises.”

The latest spending package does provide several pro-growth provisions appealing to corporations, including increased funding for medical research, childcare, and other Democratic policy priorities. But ultimately, the bruising legislative process highlighted that divided government paralysis remains intractable in the nation’s capital.

As these drawn-out fiscal policy standoffs grow increasingly commonplace, the risks of ebbing economic confidence and corporate earnings growth may become more acute for small-cap equity investors. Monitoring this governance turmoil will be crucial for calibrating prudent portfolio positioning in the months ahead.

Release – Comtech Names Telecommunications and Public Safety Leader Jeff Robertson as President of Terrestrial & Wireless Networks Business Segment

Research News and Market Data on CMTL

March 21, 2024 04:05 PM Eastern Daylight Time

CHANDLER, Ariz.–(BUSINESS WIRE)–March 21, 2024– Comtech (NASDAQ: CMTL), a global technology leader, today announced the appointment of telecommunications and public safety industry leader Jeff Robertson as the Company’s new President of its Terrestrial and Wireless Networks business segment.

Prior to joining Comtech, Robertson served as President & CEO of Intrado Life Safety, a company specializing in first responder technology in North America. Under his leadership, Robertson enhanced Intrado Life Safety’s operating structure, implemented critical digital transformation initiatives, migrated legacy products to next-generation cloud-based infrastructures, improved employee retention, and strengthened key go-to-market partnerships in under four years. Intrado Life Safety was sold in 2023 for $2.4 billion under Robertson’s leadership.

Throughout his career, Robertson has held numerous leadership roles, including Senior Vice President of Public Safety for startup innovator RapidSOS, CEO of Airbus DS Communications North America, Vice President and General Manager of Intergraph’s public safety software division, CEO of TCI – TelControl, and CML Emergency Services. He was also the founding executive director of the 9-1-1 Industry Alliance.

“Jeff will be instrumental in helping Comtech continue to grow and capitalize on core business objectives,” said John Ratigan, Interim CEO of Comtech. “Jeff brings unique insights and deep industry expertise that are well aligned with our continued One Comtech journey, terrestrial and wireless technology developments, and long-term strategies in key markets.”

As President of the Terrestrial & Wireless Networks segment, Robertson will have P&L responsibility across the enterprise. Robertson will oversee all aspects of engineering, program management, operations, new product development, system design, strategic planning, and customer engagement for all Terrestrial & Wireless Networks areas of focus.

“I am thrilled to be a part of Comtech,” said Robertson. “Comtech already enjoys a leadership position in NG-911 solutions. I am excited to lead this business forward as we continue to help states and local governments around the world to provide the best possible public safety solutions for their communities. Comtech has the right people, products and culture to capture the opportunities ahead of us.”

Robertson has been involved in the field of public safety technology for over 25 years, serving as a sworn officer and deputy sheriff. He also has extensive experience in software development for the public safety sector and was awarded a U.S. Patent for Voice Over IP Delivery of 911 calls, which is widely used across the industry today.

Robertson graduated from the executive program at the Wharton School – University of Pennsylvania and received a degree in telecommunications from Toronto Metropolitan University.

About Comtech

Comtech Telecommunications Corp. is a leading global technology company providing terrestrial and wireless network solutions, next-generation 9-1-1 emergency services, satellite and space communications technologies, and cloud native capabilities to commercial and government customers around the world. Our unique culture of innovation and employee empowerment unleashes a relentless passion for customer success. With multiple facilities located in technology corridors throughout the United States and around the world, Comtech leverages our global presence, technology leadership, and decades of experience to create the world’s most innovative communications solutions.For more information, please visit www.comtech.com.

Forward-Looking Statements

Certain information in this press release contains statements that are forward-looking in nature and involve certain significant risks and uncertainties. Actual results and performance could differ materially from such forward-looking information. The Company’s Securities and Exchange Commission filings identify many such risks and uncertainties. Any forward-looking information in this press release is qualified in its entirety by the risks and uncertainties described in such Securities and Exchange Commission filings.

Contacts

Investor Relations
Maria Ceriello
631-962-7115
Maria.Ceriello@comtech.com

Media Contact
Jamie Clegg
480-532-2523
jamie.clegg@comtech.com

Reddit’s Soaring IPO: From Online Forums to $9.5 Billion Company

The internet forum that helped launch the meme stock frenzy is now a multi-billion dollar public company itself. Reddit, the hugely popular online community made up of thousands of niche message boards, had a blockbuster stock market debut on Thursday.

Shares of Reddit, trading under the ticker RDDT on the New York Stock Exchange, skyrocketed 48% to close at $50.44, giving the company a lofty valuation of $9.5 billion. The explosive first day performance continues the hot streak for newly public tech companies in 2024 and underscores insatiable investor demand for businesses involved with artificial intelligence.

Reddit priced its initial public offering on Wednesday at $34 per share, raising around $750 million in the process with the company itself collecting $519 million. That IPO price was already at the top end of the expected range amid high demand, valuing Reddit at $6.5 billion on an exit from the private markets.

The robust valuation is a major achievement for Reddit, which was founded nearly 20 years ago in 2005 by the entrepreneur duo of Alexis Ohanian and current CEO Steve Huffman. For years, the site with its stark design and freewheeling discussion forums operated on a shoestring budget.

But Reddit’s popularity and influence exploded in recent years, fueled by the rise of viral meme culture and Internet subcultures. The company reported $804 million in revenue for 2023, up 20% from the prior year, as it started more aggressively monetizing the engaged audiences on its platform through advertising and other services.

While still unprofitable with a $90.8 million net loss last year, Reddit is now setting itself up as a major media and technology player by going public. It is the first major social platform to hit the public markets since Pinterest’s IPO in 2019.

“This is a huge milestone for Reddit and the team,” said CEO Steve Huffman, speaking to CNBC from the NYSE trading floor on the company’s debut day. “Our people and our community have built an internet culture that is now being embraced by the world.”

Reddit’s successful IPO provides an exit for some of the company’s longtime venture capital investors and big corporate backers like Tencent and Condé Nast’s parent company. But Huffman said Reddit also allocated a portion of shares in the IPO for its most devoted users and volunteer moderators who help run the site’s myriad discussion boards.

“The people make Reddit what it is,” said Huffman. “This is a chance for our most passionate folks to own a piece of that.”

Looking ahead, Reddit sees big growth potential in data licensing, particularly providing user content to artificial intelligence companies to train their language models and other software. The company revealed it has already inked data deals worth over $200 million in the next few years.

However, Reddit is facing a probe from the Federal Trade Commission over its practices of selling user data to AI firms. Regulators are examining whether proper disclosure was made to users about how their posts and comments would be monetized.

Privacy and safety issues are nothing new for Reddit, which has had to crackdown on toxic content and hate speech proliferating across its unruly message board communities. Huffman acknowledged those challenges, including the role Reddit played at the center of the meme stock mania that sent shares of GameStop and AMC soaring in bizarre market frenzies in 2021.

But as evidenced by its IPO haul, Reddit has still managed to attract both users and investors by providing an online home for all sorts of niche interests and subcultures to flourish – whether that’s stocks, cryptocurrencies, sports, hobbies, activism or adult content. And Reddit sees plenty of runway for growth by continuing to serve as the internet’s open marketplace of ideas.

“There are so many people around the world looking for their communities,” said Huffman. “We provide that, and we’re just getting started.”

Snail (SNAL) – Media Strategy Potentially Reaches New Audiences


Friday, March 22, 2024

Snail is a leading, global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PCs and mobile devices.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Delivers animated series.  The company’s highly anticipated series, ARK: The Animated Series, which stars Academy Award winning actors Michelle Yeoh and Russell Crowe, is now available on Paramount+. We believe the series can leverage Paramount’s 67.5 million subscribers to reach new audiences and potentially convert new viewers to ARK players. We view the release of ARK: The Animated Series as a significant step in the company’s crossover media strategy. 


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Eledon Pharmaceuticals (ELDN) – First Transplant Of A Pig Kidney Uses Tegoprubart To Prevent Immune Rejection


Friday, March 22, 2024

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

First Transplant Of A Genetically Modified Kidney To A Human. Eledon announced that tegoprubart, its drug in development to prevent organ transplant rejection, was used in the first transplant of an engineered pig kidney into a human patient. The kidney was genetically engineered by eGenesis, Inc, a company that has been collaborating with Eledon. Tegoprubart is currently in a Phase 2 clinical trial testing it against tacrolimus in prevention of kidney transplant rejection.

Eledon Has A Research Collaborated With eGenesis. The pig kidney was engineered by eGenesis, Inc, a company that formed a research collaboration with Eledon in January 2023. eGenesis has proprietary technology for engineering genetic changes to animal organs to make them compatible for transplantation into humans. As described in our Research Note on October 16, these genetic changes reduce the cross-species immunological barriers. The agreement allows eGenesis to use tegoprubart in its xenotransplantation research.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

1·800·Flowers.com, Inc. (FLWS) – Very Near Term View A Little Less Rosy


Friday, March 22, 2024

For more than 45 years, 1-800-Flowers.com has offered truly original floral arrangements, plants and unique gifts to celebrate birthdays, anniversaries, everyday occasions, and seasonal holidays, and to deliver comfort during times of grief. Backed by a caring team obsessed with service, 1-800-Flowers.com provides customers thoughtful ways to express themselves and connect with the most important people in their lives. 1-800-Flowers.com is part of the 1-800-FLOWERS.COM, Inc. family of brands. Shares in 1-800-FLOWERS.COM, Inc. are traded on the NASDAQ Global Select Market, ticker symbol: FLWS.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Highlights from New York NDR. This report features a recent Non-Deal Roadshow in New York with Bill Shea, Chief Financial Officer, and Andy Milevoy, Sr. Vice President, Investor Relations. In our view, the fireside chat discussion highlighted the dynamic revenue and cash flow growth opportunities, both organically and through acquisitions, and its solid financial position, all against the backdrop of favorable, long term secular trends toward e-commerce.  

Very near term challenges. While most commodities have moderated, the company is still adversely affected by stubbornly high cocoa and sugar prices. Cocoa prices are not likely to moderate until 2025, a factor of drought conditions in Africa. In addition, while ocean freight prices are likely to be constrained as new ships come on line, domestic shipping costs are expected to increase. 


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

AZZ Inc. (AZZ) – Stock due for a pause after recent strength, rating lowered


Friday, March 22, 2024

Michael Heim, Senior Vice President, Equity Research Analyst, Energy & Transportation, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

We are lowering our rating on the shares of AZZ to Market Perform with the stock solidly above our price target. The shares of AZZ have risen sharply in recent months and now trade above our $75 price target. At current prices, the shares trade at 16 times our recently raised fiscal 2025 earnings estimate, a multiple similar to its peers. Our investment premise for the shares of AZZ had been that its multiples would expand as the company’s balance sheet improved. This has largely come true.

A Market Perform rating does not mean we think the stock wont continue to rise. The company continues to report favorable results and lay the foundation for future growth. Construction of a new factory is nearing completion and financing costs are decreasing. A recent debt refinancing is expected to reduce financing costs by $5 million allowing us to raise our fiscal 2025 earnings estimate. With sales growing at a 3-5% rate and margins rising with a shift towards AZZ’s Metal Coating business, we expect solid earnings growth over the next few years.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Release – MAIA Biotechnology Welcomes Prominent Medical Oncology Scientist Dr. Saadettin Kilickap to Its Scientific Advisory Board

Research News and Market Data on MAIA

March 21, 2024 3:00pm EDT

  • Acclaimed academic researcher has led 40+ multicenter phase 2 and phase 3 clinical studies

CHICAGO–(BUSINESS WIRE)– MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the appointment of Professor Saadettin Kilickap, M.D. to its Scientific Advisory Board (SAB).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321173734/en/

Professor Saadettin Kilickap, M.D., Scientific Advisor to MAIA Biotechnology (Photo: Business Wire)

Dr. Kilickap is a professor at the Istinye University Faculty of Medicine, Department of Medical Oncology, Liv Hospital in Turkey. His research focuses on medical oncology and cancer epidemiology, including solid tumors such as lung cancer, breast cancer, melanoma, and gastrointestinal system cancers, as well as targeted therapies and immunotherapy.

“Saadettin has served as principal or sub-investigator in more than 40 national and international multi-center phase 2 and phase 3 studies, many of which were related to lung cancer,” said Chief Executive Officer Vlad Vitoc, M.D. “He is a prominent voice on medical oncology and cancer epidemiology, with a special interest in quality of life for cancer patients. We are delighted to welcome him as Scientific Advisor as we begin to clear major clinical inflection points this year and progress with our groundbreaking cancer research.”

Prior to his current appointment, Dr. Kilickap was a professor at the Preventive Oncology Department of Hacettepe University Cancer Institute of Turkey. Earlier he worked in the Department of Hematology-Oncology at Regensburg University in Germany and was a faculty member at the Sivas Cumhuriyet University Faculty of Medicine, Department of Internal Medicine, in Turkey.

Dr. Kilickap graduated with honors from Gazi University Faculty of Medicine and went on to complete his internal medicine residency training at Hacettepe University Faculty of Medicine, both located in Ankara, Turkey. He completed his fellowship training at Hacettepe and became a medical oncology specialist in 2009. In the same year, he graduated from the Cancer Epidemiology Master’s Program at the Hacettepe University Oncology Institute, Department of Preventive Oncology.

Dr. Kilickap has authored more than 240 scientific articles published in international peer-reviewed journals, and delivered more than 50 poster presentations at international congresses.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

Forward Looking Statements

MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240321173734/en/

Investor Relations Contact
+1 (872) 270-3518
ir@maiabiotech.com

Source: MAIA Biotechnology, Inc.

Released March 21, 2024

Breakthrough: First Genetically Modified Pig Kidney Transplanted into Human

In a groundbreaking medical procedure, surgeons at Massachusetts General Hospital have successfully transplanted a genetically modified pig’s kidney into a human patient – the first xenotransplantation of its kind. This historic operation, performed on March 16th, 2024, provides hope that xenotransplantation could one day help alleviate the chronic shortage of human organs available for those desperately awaiting a life-saving transplant.

The recipient was a 62-year-old man suffering from end-stage kidney disease. After his body initially accepted the pig kidney, a drug regimen was immediately administered to prevent rejection, including the experimental anti-rejection therapy tegoprubart developed by Eledon Pharmaceuticals.

“This first-ever kidney xenotransplant marks a pivotal moment for the transplant community,” stated David-Alexandre C. Gros, M.D., CEO of Eledon Pharmaceuticals. “We are thankful for the opportunity to participate in this landmark procedure as we work to develop tegoprubart as a new and potentially superior immunosuppressive option for transplant patients.”

Preventing Rejection Key to Xenotransplant Success
The greatest challenge in xenotransplantation is preventing the recipient’s body from violently rejecting the foreign organ. Tegoprubart targets a protein called CD40 ligand (CD40L) that plays a central role in activating the immune system’s responses against the transplanted organ.

“Therapies targeting CD40L, like tegoprubart, are critical to controlling the immune response to the xenograft, potentially leading to superior long-term outcomes compared to other immunosuppressive therapies,” explained Andrew Adams, M.D., Ph.D., Chief of Transplant Surgery at the University of Minnesota.

Tegoprubart has already shown promise in preventing rejection in previous pig-to-human heart xenotransplants as well as in ongoing clinical trials for human-to-human kidney transplants.

“We have seen tegoprubart be safe and well-tolerated while successfully preventing rejection and enabling above-average kidney function post-transplant when used as part of an immunosuppressive regimen in our Phase 1b kidney transplant study,” said Dr. Gros.

A Pivotal Moment of Hope
For the medical team at Massachusetts General Hospital, this pioneering procedure represents a significant milestone with profound implications for the future of transplant medicine.

“Xenotransplantation represents a unique approach with the potential to provide patients with additional options to access life-saving treatments in a timely manner,” said Dr. Leonardo V. Riella, Medical Director for Kidney Transplantation at MGH. “We commend the courage of our patient and look forward to continued advancements to make this option available to more patients.”

More than 90,000 Americans are currently on the national waiting list for a kidney transplant, with thousands more awaiting other life-saving organ donations. The ability to use genetically engineered animal organs could dramatically increase the supply available for transplant.

“This procedure provides hope that xenotransplantation may one day help solve the current shortage of available organs,” noted Dr. Gros. “While still at an experimental stage, it’s an exciting development for the entire transplant field.”

Critical Next Steps
Eledon is conducting further preclinical studies evaluating tegoprubart’s ability to prevent rejection in non-human primate recipients of xenotransplanted organs. The company is also running a Phase 2 clinical trial called BESTOW directly comparing tegoprubart head-to-head against the standard anti-rejection drug tacrolimus for preventing kidney rejection in human-to-human transplants.

While this first xenotransplant procedure is an incredible medical achievement, significant additional research is still needed to prove the technique can lead to consistently successful long-term outcomes. However, this unprecedented operation has opened up a new frontier of possibilities for making organ transplants more widely available to the hundreds of thousands in need.

Take a moment to watch an intriguing panel discussion on xenotransplantation with CEO of Eledon Pharmaceuticals, Dr. DA Gros and other prominent figures in the field at NobleCon19.

Release – Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human

Research News and Market Data on ELDN

March 21, 2024

Historic kidney xenotransplantation procedure conducted at Massachusetts General Hospital

Tegoprubart administration has now been used investigationally to prevent rejection in both kidney and heart pig-to-human xenotransplantations, as well as in human-to-human kidney transplantation

Eledon recently presented results from its ongoing Phase 1b kidney transplantation study which demonstrated that tegoprubart was generally safe and well tolerated and successfully prevented rejection with post-transplant kidney function above historical averages

IRVINE, Calif., March 21, 2024 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that tegoprubart, the company’s investigational anti-CD40L antibody, was used as a component of the immunosuppressive treatment regimen following the first-ever transplant of a kidney from a genetically modified pig to a human. The procedure was completed on March 16, 2024, at Massachusetts General Hospital on a 62-year-old man living with end-stage kidney disease.

“This first-ever kidney xenotransplant marks a pivotal moment for the transplant community and provides hope that this option may one day help solve the current shortage of available organs,” said David-Alexandre C. Gros, M.D., Eledon Chief Executive Officer. “Eledon has now participated in both heart and kidney xenotransplant procedures, further demonstrating tegoprubart’s broad potential in transplant. We are thankful to the patient, the entire medical team at Massachusetts General Hospital, and our partner eGenesis for the privilege to participate in this landmark procedure as we work to achieve our goal of developing tegoprubart as a new and better immunosuppressive option for transplant patients.”

Tegoprubart is being administered to the patient investigationally as part of a regimen designed to suppress the immune system and prevent the body from rejecting the transplanted pig organ. Tegoprubart has been observed to be safe and well-tolerated in multiple studies and in multiple indications, including for the prevention of rejection following kidney transplantation.

“It is exciting to see the clinical application of xenotransplantation to a patient with end stage renal disease,” said Andrew Adams, MD, PhD, Chief, Division of Transplant Surgery, University of Minnesota. “Based on all of the studies performed in preclinical models to date, it is clear that therapies targeting CD40L, like tegoprubart, are critical to controlling the immune response to the xenograft, potentially leading to superior long-term outcomes compared to other immunosuppressive therapies. CD40L sits at the interface of the adaptive and innate immune responses which may explain why therapies designed to block it have such potent effects in xenotransplantation.”

“This procedure represents a significant milestone in the transplantation field and a promising step to address a medical crisis: the worldwide shortage of available organs,” said Leonardo V. Riella, MD, PhD, Medical Director for Kidney Transplantation at Massachusetts General Hospital. “Xenotransplantation represents a unique approach with the potential to provide patients with additional options to access life-saving treatments in a timely manner. We commend the courage of our patient and the skill of the entire team involved in the operation, and I look forward to continued advancements in research with the hope that we can make this novel treatment option available to more patients in the future.”

Multiple clinical and preclinical research efforts are currently underway to evaluate the ability of tegoprubart to reduce the risk of rejection in organ transplant. Eledon is advancing preclinical studies in which tegoprubart is being used as a part of the immunosuppression regimen designed to reduce the risk of rejection in nonhuman primate recipients in xenotransplant procedures. In parallel, Eledon is running two global clinical studies evaluating tegoprubart for the prevention of organ rejection in persons receiving a de novo kidney transplant. The company recently presented results from 11 participants enrolled in its ongoing Phase 1b kidney transplantation study, which demonstrated that tegoprubart, as part of a calcineurin inhibitor free immunosuppressive regimen, was generally safe and well tolerated and both successfully prevented rejection as well as permitted above historical average post-transplant kidney function. The company’s Phase 2 BESTOW study, assessing tegoprubart head-to-head with tacrolimus for the prevention of rejection in kidney transplantation, is currently recruiting participants, and plans to complete enrollment at the end of 2024.

About Eledon Pharmaceuticals and tegoprubart

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.

Follow Eledon Pharmaceuticals on social media: LinkedInTwitter

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. Any statements about the company’s future expectations, plans and prospects, including statements about planned clinical trials, the development of product candidates, expected timing for initiation of future clinical trials, expected timing for receipt of data from clinical trials, as well as other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “estimates,” “intends,” “predicts,” “projects,” “targets,” “looks forward,” “could,” “may,” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently uncertain and are subject to numerous risks and uncertainties, including: risks relating to the safety and efficacy of our drug candidates; risks relating to clinical development timelines, including interactions with regulators and clinical sides, as well as patient enrollment; risks relating to costs of clinical trials and the sufficiency of the company’s capital resources to fund planned clinical trials; and risks associated with the impact of the ongoing coronavirus pandemic. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors. These risks and uncertainties, as well as other risks and uncertainties that could cause the company’s actual results to differ significantly from the forward-looking statements contained herein, are discussed in our quarterly 10-Q, annual 10-K, and other filings with the U.S. Securities and Exchange Commission, which can be found at www.sec.gov. Any forward-looking statements contained in this press release speak only as of the date hereof and not of any future date, and the company expressly disclaims any intent to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:

Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com

Media Contact:

Jenna Urban
Berry & Company Public Relations
(212) 253 8881
jurban@berrypr.com

Source: Eledon Pharmaceuticals

Source: Eledon Pharmaceuticals, Inc.

Gold Prices Soar to Record Highs Amid Global Economic Turbulence

The price of gold has skyrocketed to unprecedented levels, smashing through its previous record highs as financial markets grapple with elevated uncertainty and economic turmoil worldwide. The precious yellow metal surged past $2,200 per ounce in March 2024, with many analysts forecasting prices could potentially reach $2,300 by year’s end.

Central Bank Buying Fuels Demand Surge

A major driver behind gold’s stellar rally has been the concentrated buying from the world’s central banks. Motivated by a desire to diversify reserves and hedge against financial instability, national banks have been steadily accumulating gold over the past few years. Their purchases hit an all-time high of 1,136 tons in 2023.

Leading the pack is China’s central bank, which added 62 tons to its reserves in just the first two months of 2024 alone. This buying spree represents China’s ongoing efforts to reduce exposure to the U.S. dollar amid simmering trade tensions and economic competition between the superpowers.

But China is far from the only central bank betting big on bullion. Poland’s central bank emerged as a surprise major buyer in 2023, snapping up 130 metric tons of gold as it moved to bolster its financial security buffers in the wake of the Russia-Ukraine conflict. Singapore’s monetary authority also purchased 76.5 tons last year.

Rampant Inflation Stokes Safe Haven Demand

In addition to central bank accumulation, surging consumer demand has provided another powerful upward force on gold prices across multiple major markets. Galloping inflation in many economies has amplified the yellow metal’s appeal as a store of value and hedge against currency debasement.

In Turkey, where annual inflation topped a staggering 67% in February, demand for gold jewelry and investment bullion nearly doubled in 2023 versus the prior year. With the Turkish lira plunging over 40% against the U.S. dollar, local investors piled into gold to preserve their savings from being eroded by the currency’s depreciation.

Even in relatively lower inflation environments like India, retail investment updates for gold bars, coins and jewelry have remained robust. India’s gold bar and coin demand increased 7% year-over-year, buoyed by households seeking a safe haven asset amid economic uncertainty.

China Overtakes India as Top Jewelry Consumer

China has now surpassed India as the world’s largest gold jewelry consumer market. Chinese demand for gold jewelry amounted to 603 tons in 2023, a 10% annual increase, as retail investors diversified away from underperforming asset classes like real estate and sought refuge in the perceived safety of gold.

India remains a gold jewelry powerhouse as well. Though higher prices moderated some discretionary jewelry purchases, India’s enduring cultural tradition of giving gold gifts during weddings kept consumer demand elevated. India’s gold jewelry consumption totaled 562 tons in 2023.

Economic Outlook Boosts Appeal of Non-Yielding Bullion

Looking ahead, the outlook for even higher gold prices appears increasingly supported by expectations of potential interest rate cuts amid growing fears of an economic slowdown or recession. Lower rates diminish the opportunity cost of holding non-yielding bullion versus interest-bearing assets like bonds.

Major financial institutions like the World Bank and IMF have slashed economic growth projections for 2024, citing persistent inflation, elevated borrowing costs, and supply chain disruptions. This gloomy backdrop heightens the perceived risk of central banks easing monetary policy, which could catalyze another leg higher in gold’s explosive price rally.

With its dual status as an inflation hedge and safe haven asset, gold has reclaimed its luster amidst the storm clouds gathering over the global economic horizon. As long as uncertainty and currency debasement risks persist, the precious metal’s stellar ascent may be far from over.

Take a look at Noble Capital Markets’ Senior Research Analyst Mark Reichman’s coverage universe.

Release – Euroseas Ltd. Announces Completion of Retrofits of its Intermediate Containership, M/V Marcos V, Reducing the Vessel’s Carbon Footprint

Research News and Market Data on ESEA

Maroussi, Athens, Greece – March 21, 2024 – Euroseas Ltd. (NASDAQ: ESEA, the “Company” or “Euroseas”), an owner and operator of container carrier vessels and provider of seaborne transportation for containerized cargoes, announced today it has successfully completed the installation of a number of “energy saving devices” on its 6,350 teu intermediate containership, M/V Marcos V, aiming to improve her consumption in the commercial speed range by about 25%. The investment was done in conjunction with the vessel’s scheduled dry docking and special survey and was funded by the charterer of the vessel, who contemporaneously declared their option to extend the charter by an additional minimum seven months to August 2025. In case the vessel is employed after the current charter period, the owners will refund part of the cost to the charterer, up to a maximum of 50%.

The following devices were installed on the ship:

(a) New bulbous bow

(b) A new and lighter propeller

(c) Hub vortex absorbed fins (HVAF)

(d) Pre-shrouded vanes (PSV)

(e) Silicone coating of the ship’s underwater parts

(f) LED lights

(g) Auto pilot upgrade with advanced ecology control

(h) Jacket pre-heater auto control

Aristides Pittas, Chairman and CEO of Euroseas commented: “We are pleased to announce the completion of retrofits for our M/V Marcos V, continuing our retrofitting program, as part of our efforts to minimize the carbon footprint of our fleet. As in the case of the recent retrofit of M/V Synergy Busan, we cooperated closely with the charterer to specify and fund the modifications of the vessel and share the economic benefit from the improved performance.”

About Euroseas Ltd.

Euroseas Ltd. was formed on May 5, 2005 under the laws of the Republic of the Marshall Islands to consolidate the ship owning interests of the Pittas family of Athens, Greece, which has been in the shipping business over the past 150 years. Euroseas trades on the NASDAQ Capital Market under the ticker ESEA.

Euroseas operates in the container shipping market. Euroseas’ operations are managed by Eurobulk Ltd., an ISO 9001:2008 and ISO 14001:2004 certified affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. Euroseas employs its vessels on spot and period charters and through pool arrangements.

The Company has a fleet of 20 vessels, including 13 Feeder containerships and 7 Intermediate containerships. Euroseas 20 containerships have a cargo capacity of 61,661 teu. After the delivery of six feeder containership newbuildings in 2024, Euroseas’ fleet will consist of 26 vessels with a total carrying capacity of 75,461 teu.

Forward Looking Statement

This press release contains forward-looking statements (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events and the Company’s growth strategy and measures to implement such strategy, including expected vessel acquisitions and entering into further time charters. Words such as “expects,” “intends,” “plans,” “believes,” “anticipates,” “hopes,” “estimates,” and variations of such words and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates that are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of the Company. Actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include but are not limited to changes in the demand for containerships, competitive factors in the market in which the Company operates; risks associated with operations outside the United States; and other factors listed from time to time in the Company’s filings with the Securities and Exchange Commission. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Visit our website www.euroseas.gr

Company Contact

Tasos Aslidis

Chief Financial Officer

Euroseas Ltd.

11 Canterbury Lane, Watchung, NJ 07069

Tel. (908) 301-9091

E-mail: aha@euroseas.gr

Investor Relations / Financial Media

Nicolas Bornozis

Markella Kara

Capital Link, Inc.

230 Park Avenue, Suite 1540 New York, NY 10169

Tel. (212) 661-7566

E-mail: euroseas@capitallink.com

Release – Snail Games Celebrates the Launch of ARK: The Animated Series in U.S. and Canada with Themed In-Game Skins for ARK: Survival Ascended to Broaden Market Base

Research News and Market Data on SNAL

March 21, 2024 at 8:00 AM EDT

CULVER CITY, Calif., March 21, 2024 (GLOBE NEWSWIRE) — Snail, Inc. (Nasdaq: SNAL) (“Snail Games” or “the Company”), a leading global independent developer and publisher of interactive digital entertainment, celebrates the announcement by Paramount+ today that the first six episodes of ARK: THE ANIMATED SERIES, an all-new original series based on the hit adventure video game ARK: Survival Evolved, are available to stream now exclusively on Paramount+ in the U.S. and Canada. The series will debut in all other Paramount+ international markets starting Friday, April 19. Part two of the season will debut with seven new episodes at a later date.

ARK: THE ANIMATED SERIES brings to life the epic saga of Helena Walker, a 21st-century paleontologist navigating a mysterious prehistoric world. This narrative expansion is set to captivate both gamers and mainstream audiences, providing a deeper dive into the ARK lore and offering fans and newcomers alike a new way to engage with its rich, survival-centric narrative. The launch of the series is expected to further enhance the ARK universe’s market presence nationwide and globally, reinforcing the franchise’s status in both the gaming community and mainstream entertainment.

In celebration of the series’ launch, ARK: Survival Ascended will introduce Bob’s “Dear Jane” in-game content which includes four animated character skins. The dual launch aims to broaden the market reach and penetration of the ARK universe. This new content aims to bridge the gaming experience with the animated series, offering fans additional content to enhance immersion in the ARK universe. Moreover, starting April 1st, ARK Survival Ascended (Cloud, PC, Xbox Series X|S) becomes available on Microsoft’s Game Pass, extending its reach to a wider player base.

“The launch of ARK: The Animated Series and the accompanying in-game skins mark a pivotal moment for the ARK franchise,” said Jim Tsai, CEO of Snail, Inc. “Expanding the ARK experience beyond gaming into mainstream media not only boosts our game’s appeal but also establishes ARK universe as a multidimensional brand in entertainment. This strategic move is a testament to our dedication to growing and diversifying the ARK experience for both our dedicated community and newcomers. As we continue to explore new opportunities for growth and expansion for our ARK universe and other game titles, our commitment remains to providing engaging, innovative gaming experiences that exceed player expectations.”

About Snail, Inc.- https://www.snailgamesusa.com/

Snail is a leading, global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PCs and mobile devices.

Forward Looking Statements

This press release contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this press release can be identified by the use of forward-looking words such as “anticipate,” “believe,” “could,” “expect,” “should,” “plan,” “intend,” “may,” “predict,” “continue,” “estimate” and “potential,” or the negative of these terms or other similar expressions. Forward looking statements appear in a number of places in this press release and include, but are not limited to, statements regarding Snail’s intent, belief or current expectations.

Contacts:

Investors:

investors@snail.com

Press:

media@snail.com